Diagnosis and treatment for hyperhidrosis
Reading File
Reading File
Finding Sources
Searching PubMed
hyperhidrosis
Searching the Web
hyperhidrosis diagnosis treatment International Hyperhidrosis Society clinical guidelines
Finding Sources
Finding Sources
Reading Web Page
https://www.sweathelp.org/about-hyperhidrosis/diagnosis-guid…
Hyperhidrosis is sweating beyond what is needed for temperature control. It may be primary focal or secondary to a medication or illness.
Diagnosis
1. Decide whether it is primary or secondary
Primary focal hyperhidrosis typically:
- Begins in childhood or adolescence
- Affects both sides similarly, most often the palms, soles, underarms, face/scalp
- Occurs at least weekly and disrupts daily activities
- Often has a family history
- Stops during sleep
- May be triggered by emotion, heat, or exercise
A commonly used clinical definition is focal visible excessive sweating for at least 6 months without an apparent cause, plus at least two features above. Dermatology 2-Volume Set, 5e, lines 703-716.
Secondary hyperhidrosis is more likely when sweating:
- Is new in adulthood, generalized, asymmetric, or occurs at night
- Coincides with fever, weight loss, palpitations, tremor, flushing, pain, or other systemic symptoms
- Started after a new drug or substance
Potential causes include fever/infection, hyperthyroidism, hypoglycemia or diabetes, menopause, pregnancy, lymphoma, Parkinson disease, pheochromocytoma, alcohol/substance withdrawal, and medications. Andrews' Diseases of the Skin, lines 213-219.
2. Clinical assessment
A clinician should ask about:
- Distribution and duration of sweating, triggers, and sleep sweating
- Family history
- Medication and substance use, including antidepressants, opioids, hypoglycemic medicines, and others
- Symptoms suggesting endocrine disease, infection, malignancy, neurologic disease, or menopause
Examination targets the involved areas and signs of systemic disease. Testing is not routinely required for classic primary focal hyperhidrosis, but may include glucose testing, thyroid tests, CBC, and other targeted investigations if secondary causes are suspected. The International Hyperhidrosis Society diagnostic guidance emphasizes ruling out secondary causes first.
Severity can be tracked using the Hyperhidrosis Disease Severity Scale:
- 1-2: tolerable or only occasionally interferes
- 3-4: barely tolerable or intolerable, frequently/constantly interferes
Treatment
Treatment is selected by body site, severity, prior response, side effects, and patient preference.
First-line measures
- Use a clinical-strength antiperspirant, usually aluminum chloride or aluminum chloride hexahydrate.
- Apply to completely dry skin at night, wash off in the morning; use nightly initially, then reduce to maintenance frequency once controlled.
- Skin irritation is common. Apply only to intact, dry skin and discuss a low-potency topical steroid briefly with a clinician if dermatitis occurs.
- Wear breathable fabrics, change socks/clothes as needed, and use absorbent shoe inserts for plantar sweating.
Textbook first-line topical options include over-the-counter antiperspirants and aluminum chloride hexahydrate 10%-35%. Fitzpatrick's Dermatology, lines 2864-2868.
Site-specific escalation
| Site | Usual next options |
|---|---|
| Underarms | Prescription topical anticholinergic, botulinum toxin injections, microwave thermolysis in suitable patients |
| Palms/soles | Tap-water iontophoresis, then botulinum toxin if needed |
| Face/scalp | Carefully selected topical anticholinergic or botulinum toxin by an experienced clinician |
| Multiple sites/generalized symptoms | Treat underlying cause if present; consider oral medication under medical supervision |
Iontophoresis: Particularly effective for palms and soles. Hands or feet are placed in shallow water trays while a mild electrical current is passed. Initial frequent sessions are followed by maintenance. It may be unsuitable with certain implanted electrical devices or during pregnancy, so confirm with the treating clinician.
Botulinum toxin injections: Effective for axillary and palmar sweating and can also be used for other focal sites. Benefits are temporary, so repeat treatment is required. Palmar injections can be uncomfortable and can cause temporary hand weakness. Goldman-Cecil Medicine, line 1354.
Topical anticholinergics: Options vary by country and include glycopyrronium or sofpironium preparations, particularly for axillary disease. Possible adverse effects include dry mouth, blurred vision, and pupil dilation if the medicine reaches the eyes. Wash hands after applying.
Oral anticholinergics: Glycopyrrolate or oxybutynin can help widespread or refractory focal sweating, but require clinician prescription and monitoring. Side effects can include dry mouth, constipation, urinary retention, blurred vision, fast heart rate, overheating, and cognitive effects. They may be inappropriate in some people, including those with narrow-angle glaucoma or urinary retention.
Procedures for severe refractory disease:
- Axillary microwave thermolysis or local sweat-gland procedures in selected cases
- Endoscopic thoracic sympathectomy for very severe, treatment-resistant palmar hyperhidrosis only. It can cause persistent compensatory sweating elsewhere, so it should be considered cautiously.
When to seek prompt medical review
Arrange a medical assessment promptly if sweating is new or rapidly worsening, mainly occurs at night, is generalized, or comes with:
- Fever, unexplained weight loss, swollen lymph nodes
- Chest pain, shortness of breath, fainting
- Palpitations, tremor, or heat intolerance
- Confusion, weakness, or symptoms of low blood sugar
For most people with the typical focal pattern, a dermatologist can confirm the diagnosis and build a stepwise treatment plan. Current treatment algorithms are available through the International Hyperhidrosis Society.
Recent evidence note: a 2025 systematic review found evidence supporting sofpironium for primary hyperhidrosis, primarily axillary disease (PMID: 39668771). Recent reviews also show that primary hyperhidrosis is associated with anxiety and depression, so screening for its quality-of-life impact is appropriate (PMIDs: 39351777, 42458641).
This is a shared conversation. Sign in to Orris to start your own chat.